Article

Preliminary trials with Light-Adjustable Lens are promising

San Francisco-April 13-The Light-Adjustable Lens (LAL) has entered humanclinical trials with promising results. Four humans-one blind and threewith sight-have received the lens, noted Robert K. Maloney, MD, chief medicalofficer, Calhoun Vision Inc, Pasadena, CA, who spoke at dinner gatheringin San Francisco.

Related Videos
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
Iantrek, Inc. announces 1-Year outcomes from the CREST Registry for bio-interventional glaucoma treatment
December 13th 2024

Iantrek, Inc. announces 1-Year outcomes from the CREST Registry for bio-interventional glaucoma treatment

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

Study: Elevated NLR and SII levels linked to higher risk of cystoid macular edema
December 13th 2024

Study: Elevated NLR and SII levels linked to higher risk of cystoid macular edema

Robert Chang, MD, discusses the impact of large language models on glaucoma care and AI in ophthalmology
November 5th 2024

Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD

4-Year research validates DOT 0.2 spectacle lenses as early myopia treatment
December 12th 2024

4-Year research validates DOT 0.2 spectacle lenses as early myopia treatment

Enhancing precision in GA imaging
December 12th 2024

Enhancing precision in GA imaging

© 2024 MJH Life Sciences

All rights reserved.